Molecular Geriatrics Corporation

Abbott Laboratories Corporation

Molecualr Geriatrics Corporation

Daniel Joseph Kerkman

John F DeBernardis

Raymond Paul Zinkowski

Biswanath De

Andrew O Stewart

Dee W Brooks

Jonathan G Martin

Steven Armen Boyd

Martin Winn

William J McClellan

Saul H Rosenberg

Anthony K Fung

Thomas W Von Geldern

Pramila A Bhatia

Anwer Basha

Fatima Z Basha

Diane M Yamamoto

Thomas M Zydowsky

Kazumi Shiosaki

Andrew Stewart Tasker

Howard E Morton

Robert E Zelle

James B Summers, Jr

Jeffrey A Kester

Peter Davies

Kenneth P Spina

Russell E Kohnken

Disclosed are compounds of formula I: wherein

Certain substituted 1-aryl-3-piperazine-1'-yl propanones

The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.

Purified antigen for Alzheimer's disease and methods of obtaining and using same

Methods for treating or preventing alzheimer's disease using substituted 1-aryl-3-piperazin-1&prime;-yl propanones

Methods for treating or preventing alzheimer's disease using substituted 2-aryl-3-morpholinopropanones

Certain substituted 1-aryl-3-piperazin-1&prime;-yl propanones

Disclosed are compounds of formula I: or the pharmaceutically acceptable salts thereof wherein

Certain substituted 1-aryl-3-piperazin-1'-yl propanones

Disclosed are compounds of formula I: ##STR1## wherein X is selected from oxygen, sulfur and NR; wherein

Methods for treating or preventing Alzheimer's Disease using substituted

Certain substituted 1-aryl-3-morpholinopropanones to treat Alzheimer's

Disclosed are compounds of formula I: ##STR1## wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl;

Substituted 1-aryl-3-piperazin-1'-yl propanones

Disclosed are compounds of formula I: ##STR1## or the pharmaceutically acceptable salts thereof wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl;

Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat

Compounds of the structure ##STR1## where p and q are zero or one, but cannot both be the same, M is a pharmaceutically acceptable cation or a metabolically cleavable group, B is a valence bond or a straight or branched alkylene group, R is alkyl, cycloalkyl or --NR.sup.1 R.sup.2, where R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted carbocyclic aryl, furyl, benzo[b]furyl, thienyl, or benzo[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.

Furyl and thienyl alkynyl-N-hydroxy urea derivatives

Acetylene derivatives having lipoxygenase inhibitory activity

The present invention provides a tetrahydroisoquinoline compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof which is an antagonist for alpha-2 adrenoreceptors and/or which inhibits biogenic amine uptake.

Tetrahydroisoquinolines as alpha-2 antagonists and biogenic amine uptake

Compounds are disclosed having the formula: ##STR1## wherein the substituents are defined herein. The compounds of the invention are angiotensin II receptor antagonists.

Angiotensin II receptor antagonists

Compounds are disclosed having the formula: ##STR1## The compounds of the invention are angiotensin II receptor antagonists.

Growing community of inventors

Lake Villa, IL, United States of America

Daniel Joseph Kerkman